Apr 10, 2025 08:30AM
Oct 22, 2024 09:01AM
Oct 22, 2024 09:00AM
Sep 12, 2024 09:01AM
Sep 12, 2024 09:00AM
Mar 7, 2024 04:01PM
Dec 26, 2023 09:00AM Oncternal Therapeutics Inc. (ONCT) Updates the Status of its Phase 1/2 Study of ONCT-808
Dec 26, 2023 09:00AM
Nov 9, 2023 04:01PM
Oct 26, 2023 09:00AM
Aug 10, 2023 04:01PM
Aug 3, 2023 04:05PM
May 4, 2023 04:01PM
Mar 9, 2023 04:01PM Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results
Dec 10, 2022 03:00PM
Nov 3, 2022 04:01PM
Oct 3, 2022 04:32PM
Oct 3, 2022 04:31PM
Sep 27, 2022 09:00AM
Aug 9, 2022 04:05PM
Jul 14, 2022 04:01PM Oncternal Therapeutics (ONCT) Collaborates with Pharmacyclics to Advance Zilovertamab Phase 3 Study in combination with Ibrutinib for Patients with MCL
Jul 14, 2022 04:01PM
Jun 10, 2022 09:00AM
May 26, 2022 05:15PM
May 5, 2022 04:01PM
Apr 13, 2022 08:31AM
Apr 13, 2022 08:30AM
Mar 10, 2022 04:01PM Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2021 Financial Results
Jan 20, 2022 04:05PM
Jan 5, 2022 09:21AM
Jan 4, 2022 05:58PM
Jan 4, 2022 04:01PM
Jan 4, 2022 04:01PM
Dec 13, 2021 08:08AM
Dec 13, 2021 08:00AM Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2021
Nov 15, 2021 08:00AM
Nov 4, 2021 04:05PM
Sep 1, 2021 04:01PM
Aug 5, 2021 04:01PM
May 19, 2021 05:31PM
May 19, 2021 05:30PM
May 19, 2021 05:01PM Oncternal Therapeutics Presents Updated Interim Data for Cirmtuzumab in Combination with Ibrutinib at ASCO 2021
May 6, 2021 04:01PM
Apr 28, 2021 10:00AM
Apr 12, 2021 04:41PM
Apr 12, 2021 07:00AM
Apr 7, 2021 09:29AM
Mar 18, 2021 04:38PM
Mar 11, 2021 04:01PM Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2020 Financial Results
Feb 22, 2021 05:33PM

322,248 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All